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Background/aims In Portugal, so far, there is no study
or even accurate data on the prevalence of diabetic
retinopathy (DR), based on a large representative sample
and on a long-term follow-up. The objective of our study
was to determine the prevalence of DR based on a
national screening community-based programme.
Methods A 5-year retrospective analysis of the
RETINODIAB screening programme results was
implemented in Lisbon and Tagus Valley area between
July 2009 and October 2014. We estimated the
prevalence of retinopathy for all patients with type 2
diabetes and studied the association between known risk
factors and retinopathy emergence at their ﬁrst screening.
Results Throughout this period, from a total of 103 102
DR readable screening examinations, 52 739
corresponded to patients who attended RETINODIAB
screening at entry. Globally, DR was detected in 8584
patients (16.3%). Of these, 5484 patients (10.4%) had
mild non-proliferative (NP) DR, 1457 patients (2.8%) had
moderate NPDR and 672 (1.3%) had severe NPDR.
Finally, 971 patients (1.8%) had proliferative DR requiring
urgent referral to an ophthalmologist. The presence of
any DR, non-referable DR or referable DR was strongly
associated with increasing duration of diabetes and
earlier age at diagnosis.
Conclusions The prevalence rate of DR in our study
(16.3%) was slightly lower than other published
international data. The RETINODIAB network proved to
be an effective screening programme as it improved DR
screening in Lisbon and Tagus Valley surrounding area.
INTRODUCTION
Diabetic retinopathy (DR) is the leading cause of
legal blindness in the working-aged population of
industrialised societies.1–3 In 2013, 382 million
people had diabetes; this number is expected to
rise to 592 million by 2035, according to the
International Diabetes Federation (IDF).4 5
It is well established that the effectiveness of the
laser treatment depends on the accuracy and timely
treatment of DR among patients with diabetes mel-
litus, particularly those with a high risk of DR.6
Indeed, DR represents an excellent paradigm for
screening as laid out in the principles for screening
of human disease described by Wilson and Jungner
in 1968.7 8
In order to decrease by about 30% the new cases
of blindness caused by diabetes, the declaration of
St. Vincent (1989) called for the implementation of
national strategies for screening for DR in a system-
atic manner.9 WHO, IDF and the Directorate-
General of Health (DGS) co-organised (1997) the
Fourth Meeting in Lisbon for the Implementation
of the St. Vincent Declaration on Diabetes Care and
Research in Europe, which was attended by dele-
gates from 60 countries.10 This conference rein-
forced once again the need for greater engagement
from all signatory countries for the St. Vincent
Declaration in order to address diabetes complica-
tions, particularly DR. This international challenge
was strengthened at the Liverpool meeting in
2005.11 Despite all, it is only in the last decade that
signiﬁcant progress has been made in implementing
screening programmes to detect and monitor DR.
Portugal currently has a population of 10.6 million,
predominantly Caucasian, whose majority (around
8.5 million) is located on the western coast (∼80%).12
According to the National Observatory for Diabetes,
nearly one million Portuguese have diabetes, the
equivalent to 13% of the population between 20 and
79 years.13 Of these, about 400 000 people are
undiagnosed. It is imperative that these people are
identiﬁed through early diagnosis in order to signiﬁ-
cantly reduce the incidence of serious complications.
The Portuguese Diabetes Association (APDP) is the
world’s oldest diabetes association and a senior
member of the IDF. From the moment it was founded,
early in the 20th century, APDP has been driven by a
single overarching objective: to improve the quality of
life of people with diabetes. Involved nationally in dia-
betes advocacy and the provision of education, as well
as the delivery of care, APDP has become a key player
in the healthcare arena in Portugal.
Following a pilot regional DR screening pro-
gramme which was launched in 2008, the Diabetic
Retinopathy Screening Service for Lisbon and
Tagus Valley—RETINODIAB—was commissioned
and driven by APDP. This screening programme is
supported by the Regional Health Administration
of Lisbon and Tagus Valley (ARSLVT) and follows
the norms of the DGS, which is a public body of
the Ministry of Health. The major aim of the pro-
gramme was to identify all undiagnosed sight-
threatening DR in order to ensure timely onward
referral to Lisbon area hospital eye services.
Herein, the authors describe the ﬁrst Portuguese
study regarding the prevalence of DR, as well as
focus on the screening programme for DR (2009–
2014) implemented in the area of Lisbon and
Tagus Valley.
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METHODS
The RETINODIAB network
RETINODIAB (Study Group for Diabetic Retinopathy
Screening) is a m-health screening system carried out by APDP,
which focuses on clinical aspects of DR screening. Its primary
aim is to promote the advancement of knowledge on all aspects
of DR through an active cooperation between ophthalmologists
and other specialists such as endocrinologists, internists and
neurologists. Additionally, APDP has fostered the development
of important scientiﬁc studies in epidemiology and diabetology
in Portugal.14 15
Lisbon and Tagus Valley area
Lisbon and Tagus Valley is one of the ﬁve Regions of Portugal
(Nomenclature of Territorial Units for Statistics (NUTS) II divi-
sions). It corresponds to 13% of the Portuguese territory, it has
a population of 3.7 million (34.7% of the total population) and
it represents 44% of the national Gross domestic product
(GDP). There are 15 primary care groups (ACES) in this area
(ﬁgure 1) organised according to the ﬁve existing NUTS III
(subregions: Greater Lisbon, Setúbal Peninsula, Middle Tagus
and Lezíria West Coast).
APDP screening protocol—RETINODIAB
The RETINODIAB screening programme was held in several
primary care health units covered by the APDP protocol. Each
screening centre is equipped with a non-mydriatic camera
(model CR-2, Canon, Tokyo, Japan). Two 45° non-stereoscopic
retinal digital photographs per eye were taken in a scotopic
environment, one centred on the posterior pole and the other
on the optic disc. Despite all efforts, in several patients it was
impossible to obtain an image with minimum quality. In these
speciﬁc cases, orthoptists have proceeded to iatrogenic pupil
dilation. The remaining possible causes for deﬁcient acquisition
of fundus were documented in the clinical report and those
patients were referred to a specialist within a maximum period
of 3 months. After the capture of images, they are compressed
in the Digital Imaging and Communications in Medicine
(DICOM) protocol and transmitted through the internet to
APDP reading centre. All images were classiﬁed according to
The International Clinical Diabetic Retinopathy Scale.16 As clin-
ically signiﬁcant macular oedema is not discernible on non-
stereoscopic images, maculopathy was deﬁned as the presence of
hard exudates or haemorrhages within 1 disc diameter of the
fovea. Patients who had undergone panretinal laser treatment
Figure 1 Regional Health Administration of Lisbon and Tagus Valley geographic area.
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were classiﬁed as having proliferative retinopathy. Both eyes
were assessed for DR and the worse grade from the two eyes
was used in the analysis. Retinal images were considered not
gradable if retinas of both eyes could not be visualised properly
—that is, retinal vessels were not visible within 1 disc diameter
of the fovea and ﬁne vessels were not visible across the surface
of the optic disc. Where only one eye was gradable, the presence
or absence of DR relied on this eye. The reader-automatically
generated report displays diagnosis of DR level, diagnosis of
non-diabetic ocular disorders and recommendations for
follow-up (ﬁgure 2).
APDPSoft software
The APDPSoft is a software developed since 1999, which
accompanies the evolution of the services provided by the
APDP. Currently, this software supports and monitors several
valences, especially in terms of clinical data ﬁle, markings man-
agement, laboratory parameters, invoicing the health subsys-
tems, integration of numerous diagnosis equipments as well as
an effective liaison with the electronic services of the Ministry
of Health. It makes the storage of clinical data, fundus photo-
graphs and statistics. All stored images were downloaded by cer-
tiﬁed ophthalmologists at the RETINODIAB Reading Centre
comprising three readers.
Statistical methods
The features of the study participants were described using
means (SD) for continuous variables and percentages for cat-
egorical variables. The age at diagnosis was categorised into
four groups (40–49 years, 50–59 years, 60–69 years and
>70 years) for all analyses at ﬁrst screening. The duration of
diabetes was discretised into four categories (<5 years, 5–9
years, 10–15 years and >15 years). Adjusted ORs and corre-
sponding 95% CIs were calculated. Furthermore, we deﬁned
referable diabetic retinopathy (RDR) to all patients graded as
moderate non-proliferative (NP) DR, severe NPDR or prolifera-
tive retinopathy DR (with or without maculopathy) or maculo-
pathy with mild retinopathy. This category relates to those who
would, according to the guidelines, need referral to the hospital
eye service for further clinical evaluation. Univariable and
multivariable logistic regression models were used to assess the
association of the collected variables with retinopathy status,
separately for each subset of diabetes (any DR; RDR; non-
referable diabetic retinopathy (NRDR)). A level of signiﬁcance
of α=0.05 was considered. All data were analysed using the
Statistical Package for the Social Sciences for Windows V.22.0
(IBM Corp. Released 2013. IBM SPSS Statistics for Windows,
V.22.0. Armonk, New York: IBM Corp.).
RESULTS
Our 5-year retrospective analysis included data for all patients
with type 2 diabetes, diagnosed over the age of 40 years, and
who attended APDPSP between July 2009 and October 2014.
Throughout this period, from a total of 103 102 DR readable
screening examinations, 52 739 corresponded to patients who
attended RETINODIAB screening at entry. The baseline features
of study participants are included in table 1. Patients’ mean age
is 69.13 (SD=11.13) years. Women accounted for 49.6%
(n=26 149) of all patients. The mean duration of diabetes was
8.5 years (SD=7.89).
Overall, not all screening examinations resulted in assessable
images. In our present study, retinal photographs of at least one eye
could not be graded in 2757 of the 55 496 total screening patient
examinations performed at entry (4.96%). This subset of patients
was not included in the ﬁnal group used to calculate several preva-
lence rates (total number of DR diagnoses performed).
The prevalence of the different categories of DR is shown in
table 2, regarding to the total number of assessable images.
Globally, DR was detected in 8584 patients (16.3%). Of
these, 5484 patients (10.4%) had mild NPDR, 1457 patients
(2.8%) had moderate NPDR and 672 (1.3%) had severe NPDR.
Finally, 971 patients (1.8%) had proliferative DR requiring
urgent referral to an ophthalmologist. A total of 732 patients
(1.4%) had maculopathy.
The results of the multivariable logistic regression analysis are
shown in table 3.
Men had increased odds of all severities of DR compared
with women. The odds of all grades of DR increased with the
duration of diabetes. There was a 2.50-fold, 4.99-fold and
8.20-fold increased odds of any DR associated with a duration
Figure 2 Layout for a reader-automatically generated report before its execution.
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of diabetes of 5–9, 10–15 and≥15 years compared with
<5 years (reference subgroup) and a 2.38-fold, 4.19-fold and
5.03-fold increased odds of NRDR in the same subgroups,
respectively. For RDR subset of patients, the odds increased by a
factor of 2.80 with a known duration of diabetes of 5–9 years
and 6.37-fold for a known duration of diabetes of 10–15 years.
Finally, for patients with a duration over 15 years the odds
increased 12.43-fold compared with the reference subgroup.
Additionally, the ORs of any DR, NRDR and RDR groups
were signiﬁcantly lower with the increasing of age at diagnosis
of diabetes. For instance, the odds of any DR increased to 1.12,
to 1.48 and to 2.00 in the age ranges 60–69 years, 50–59 years
and > under 50 years, respectively, compared with the reference
group (> 70 years).
Regarding insulin treatment, all patients with diabetes under
insulin therapy had a signiﬁcant increased odds for all different
DR subgroups.
DISCUSSION
Until now, there have been no studies addressing the prevalence
of DR in Portuguese type 2 diabetic population, which include a
large sample size and a long-term follow-up.
Diabetes has a high prevalence in Portugal. The PREVADIAB
Study14 which was carried out by APDP found a diabetes preva-
lence of 11.7%, with a signiﬁcant difference between men
(14.2%) and women (9.5%). While 6.6% (approximately 508
000 people) had previously been diagnosed with diabetes,
5.1% (around 393 000 persons) were undiagnosed. On the
other hand, the prevalence of ‘pre-diabetes’ (impaired fasting
glucose, impaired glucose tolerance or both) in the population
was 23.3%. In our study, we reported a prevalence of any DR,
NRDR and RDR in patients with type 2 diabetes of 16.3%,
10.4% and 5.9%, respectively.
The teleophthalmology network constitutes an efﬁcient
means to overcome the lack of ophthalmologists.17 In accord-
ance with the aforementioned, Portugal may have about one
million people with diabetes, of whom 700 000 diagnosed and
on medical treatment and who should be consulted annually
according to the criteria stated above. According to the
Portuguese Ophthalmology Society (SPO), each of the 930
Portuguese ophthalmologists (2012 data) would have to observe
about 753/each year, an infeasible number in terms of logistics
specialty requirements. Moreover, screening centres or mobile
units using non-mydriatic cameras should be allocated in areas
with a high rate of poverty and a low number of ophthalmolo-
gists, like the West Region of Portugal, which is covered by
RETINODIAB programme. Additionally, the centralisation of
the network around a central reading headquarters provides a
quality control and uniformity between graders.
The epidemiological studies addressing DR prevalence in type
2 diabetes have varied worldwide, at least partly due to different
ethnic populations and different sample sizes.18 19 Nevertheless,
the comparison of the DR prevalence rates between published
studies is difﬁcult due to the lack of uniformity regarding the
different grading protocols employed. In France, Massin et al
carried out several epidemiological studies addressing DR
screening in Paris and the surrounding area.20 They documented
a prevalence of any DR around 24%. Several UK screening pro-
grammes evaluated the prevalence of DR for type 2 diabetes.
The Scottish programme ascertained the DR prevalence in
47 090 newly diagnosed patients with type 2 diabetes and
reported at 19.3% for any DR and 1.9% for RDR.21
Furthermore, Thomas et al22 undertook a cross-sectional ana-
lysis of 86 390 patients with type 2 diabetes in Wales. They
documented a prevalence of any DR and sight-threatening DR
of 30.3% and 2.9%, respectively. Similarly, the presence of DR,
non-sight-threatening and sight-threatening, was strongly asso-
ciated with either variables: increasing duration of diabetes and
earlier age at diagnosis. In Iceland, the prevalence of DR was
higher in type 2 diabetes, estimated at 41.0%.23 The prevalence
rate of DR in our study (16.3%) was slightly lower than other
published data. Indeed, all patients previously diagnosed with
DR had been already previously forwarded, and only patients
whose retinal status was unknown were included in this study.
Regarding logistic regression analysis, the duration of diabetes
was a signiﬁcant risk factor for the presence of any DR, NRDR
and referable diabetic retinopahy (RDR) in subjects with type 2
diabetes. Multivariable adjusted ORs were much higher in all
subgroups, in the longer time frame (over 15 years), compared
with other shorter periods of time. The strong association with
disease duration demonstrates the importance of early detection
and enrolling to a screening programme. Moreover, a later age
Table 1 Baseline features of study participants at time of first
screening event
Features Type 2 diabetic patients
Total number of patients screened 55 496
Total number of diagnoses done* 52 739
Patients screened with unassessable images 2757
Gender n (%)
Male 26 590 (50.4)
Female 26 149 (49.6)
Mean age, years 69.13 (11.13)
Mean age at diagnosis, years 60.63 (12.15)
Mean duration of diabetes, years 8.5 (7.89)
Treatment of diabetes
Oral hypoglycemic agents/diet only 50 581 (95.9)
Insulin 2157 (4.1)
*Total number of examinations with gradable photographs (used to calculate
prevalences).
Table 2 The prevalence of diabetic retinopathy (DR) at first
screening for all patients successfully screened
DR status Patients Per cent 95% CI
Total 52 739 100%
No DR 44 155 83.7
Any DR 8584 16.3% (16 to 16.5)
Mild NPDR 5484 10.4 (10.1 to 10.7)
Moderate NPDR 1457 2.8% (2.6 to 2.9)
Severe NPDR 672 1.3% (1.2 to 1.4)
PDR 971 1.8% (1.7 to 2.0)
Maculopathy 732 1.4% (1.3 to 1.5)
Non-referable DR
Mild NPDR without maculopathy 5258 9.99% (9.9 to 10.1)
Referable DR 3326 6.31% (6.2 to 6.4)
Mild NPDR with maculopathy 226
Moderate NPDR without maculopathy 1220
Moderate NPDR with maculopathy 237
Severe NPDR without maculopathy 516
Severe NPDR with maculopathy 156
PDR without maculopathy 858
PDR with maculopathy 113
NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
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of diagnosis has a protective effect regarding all grades of DR.
Indeed, all patients who were diagnosed over the age of
70 years have twofold lower risk of developing any DR com-
pared with all patients with diabetes diagnosed under 50 years
old. This is in accordance with several studies that advise a vari-
able schedule distribution of screening intervals according the
individual patients’ risk. In fact, increasing the length of the
screening intervals for lower risk cases would involve less
screening episodes, with resulting beneﬁts in terms of health
costs.24
The main purpose of RETINODIAB implementation was to
improve DR screening in Lisbon and Tagus Valley surrounding
area in order to efﬁciently perform, within an acceptable time
frame, all eye examinations according to the guidelines of the
DGS.25
This study provides the ﬁrst estimate of the prevalence of DR
for subjects over the age of 40 years and not receiving ophthal-
mological assistance in Portugal. In line, to the best of our
knowledge, this study represents the second largest reported
international community-based DR screening network. We will
continue to follow these patients to better deﬁne all clinical and
epidemiological data regarding this diabetic population.
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